Functional dyspepsia Medical Services in China

Functional dyspepsia (FD) is a chronic, heterogeneous disorder of the upper gastrointestinal tract characterized by persistent or recurrent epigastric pain or discomfort—such as burning, early satiety, postprandial fullness, or nausea—in the absence of structural, biochemical, or metabolic abnormalities that could explain the symptoms. It is classified under disorders of gut–brain interaction (formerly functional gastrointestinal disorders) and diagnosed using Rome IV criteria after excluding organic causes like peptic ulcer disease, gastric cancer, gastroesophageal reflux disease (GERD), celiac disease, or Helicobacter pylori infection via endoscopy, serology, breath testing, or histopathology. Pathophysiologically, FD involves complex interplay among visceral hypersensitivity, impaired gastric accommodation and motility (e.g., delayed gastric emptying or antral hypomotility), low-grade mucosal inflammation, altered gut microbiota composition, and central nervous system dysregulation—including heightened perception of normal gastric signals and stress-modulated autonomic and neuroendocrine responses. Psychosocial factors such as anxiety, depression, somatization, and early-life adversity further modulate symptom expression and severity. Epidemiologically, FD affects approximately 10–20% of the global adult population, with regional variation: prevalence in China ranges from 8% to 15%, based on community-based surveys using validated questionnaires. It is more common in women (female-to-male ratio ~1.5:1) and peaks in the third to fifth decades of life. Key risk factors include prior acute gastroenteritis (post-infectious FD), H. pylori infection (even after eradication), smoking, frequent NSAID use, high psychological distress, and dietary triggers (e.g., fatty, spicy, or acidic foods). Unlike organic diseases, FD carries no increased mortality risk—but its chronic, fluctuating nature profoundly impairs quality of life. Patients report significant reductions in work productivity (presenteeism and absenteeism), disrupted sleep, social withdrawal, diminished physical activity, and higher healthcare utilization. Many experience treatment frustration due to symptom recurrence and limited response to conventional therapies, contributing to anxiety about undiagnosed malignancy and reduced health-related quality of life scores comparable to those seen in inflammatory bowel disease or moderate asthma. Early multidisciplinary management—including dietary counseling, pharmacotherapy, cognitive-behavioral strategies, and patient education—is essential to restore functional capacity and prevent long-term disability.

Functional dyspepsia (FD) is a chronic, heterogeneous disorder of the upper gastrointestinal tract characterized by persistent or recurrent epigastric pain or discomfort, early satiety, postprandial fullness, and/or nausea—absent structural, biochemical, or metabolic abnormalities on standard diagnostic evaluation (e.g., upper endoscopy, abdominal ultrasound, routine blood tests). Per Rome IV criteria, FD is subdivided into two overlapping subtypes: postprandial distress syndrome (PDS), dominated by meal-related symptoms (early satiety, postprandial fullness), and epigastric pain syndrome (EPS), defined by epigastric pain or burning not clearly related to meals. The pathophysiology remains incompletely understood but involves complex interactions among visceral hypersensitivity, impaired gastric accommodation, delayed gastric emptying, low-grade mucosal inflammation, altered gut-brain axis signaling, and psychoneuroimmunological dysregulation.

Common causes are largely multifactorial and non-organic. Visceral hypersensitivity—heightened perception of normal gastric distension or motilin-mediated contractions—is a central mechanism, often linked to peripheral and central sensitization. Impaired gastric fundic relaxation (i.e., defective receptive relaxation) leads to exaggerated intragastric pressure during meals, triggering PDS symptoms. Approximately 30–40% of FD patients exhibit delayed gastric emptying, particularly solids, contributing to bloating and early satiety. Low-grade duodenal eosinophilic infiltration and mast cell activation have been documented in subsets of patients, suggesting immune-mediated mucosal dysfunction—even without Helicobacter pylori infection or celiac disease. Altered serotonin (5-HT) signaling in the enterochromaffin cells and enteric nervous system further modulates motility, secretion, and sensation.

Triggers are predominantly dietary and behavioral. High-fat meals delay gastric emptying and exacerbate symptoms; spicy, acidic, or caffeinated foods may provoke epigastric discomfort via transient lower esophageal sphincter relaxation or direct mucosal irritation. Large meal volumes overwhelm accommodative capacity. Psychological stressors—including acute anxiety, work-related strain, or interpersonal conflict—activate the hypothalamic-pituitary-adrenal axis and sympathetic outflow, suppressing gastric motility and amplifying nociceptive signaling. Sleep disruption and circadian misalignment impair gastric myoelectrical activity and vagal tone, worsening symptom burden.

Established risk factors include female sex (2–3× higher prevalence), younger to middle adulthood (peak incidence 30–50 years), history of acute gastroenteritis (post-infectious FD, associated with persistent duodenal lymphocytosis and barrier dysfunction), and comorbid functional disorders (e.g., irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome). Psychosocial factors—particularly trait anxiety, depression, somatization, and catastrophizing—are strongly associated with symptom severity and healthcare utilization, independent of organic pathology.

Genetic factors contribute modestly but significantly. Polymorphisms in genes regulating serotonin transport (SLC6A4, notably the 5-HTTLPR short allele), cytokine production (IL-1β, TNF-α), and toll-like receptor signaling (TLR2, TLR4) have been linked to increased FD susceptibility and symptom persistence. Twin studies suggest heritability estimates of ~20–30%, indicating polygenic influence interacting with environmental exposures. Epigenetic modifications—such as DNA methylation changes in promoter regions of stress-response genes following early-life adversity—may mediate long-term dysregulation of the gut-brain axis.

Environmental factors encompass both microbial and sociocultural domains. Early-life exposure to antibiotics, cesarean delivery, and formula feeding may alter microbiome maturation, predisposing to dysbiosis-associated gut barrier dysfunction and immune priming. Urban living, sedentary lifestyle, and chronic occupational stress correlate with higher FD prevalence. Socioeconomic disadvantage—including low health literacy, limited access to timely specialist care, and maladaptive illness beliefs—exacerbates symptom chronicity and functional impairment. Importantly, while H. pylori infection is not causative of FD per se, its eradication may improve symptoms in a subset (~10–20%) of infected individuals, likely via attenuation of low-grade gastric inflammation and neuroimmune crosstalk. Overall, FD represents a biopsychosocial disorder wherein genetic vulnerability, developmental programming, environmental exposures, and psychosocial context converge to disrupt gastroduodenal sensorimotor homeostasis.

Functional dyspepsia (FD) is a chronic, heterogeneous disorder of the upper gastrointestinal tract characterized by persistent or recurrent epigastric discomfort or pain in the absence of organic, systemic, or metabolic disease that explains the symptoms. It falls under the broader Rome IV classification of disorders of gut–brain interaction and is diagnosed exclusively after structural and biochemical abnormalities have been excluded. FD affects approximately 10–20% of the global population and is one of the most common reasons for referral to gastroenterology clinics.

Early symptoms of functional dyspepsia are often subtle and nonspecific, frequently dismissed by patients as transient indigestion or dietary intolerance. These may include intermittent postprandial fullness after modest meals, mild epigastric pressure or bloating without visible abdominal distension, and occasional nausea triggered by fatty or spicy foods. Patients may report heightened sensitivity to gastric distension during routine meals—such as feeling prematurely satiated after consuming only half a standard portion—and may begin modifying eating behaviors (e.g., eating smaller, more frequent meals; avoiding certain food groups) before seeking medical attention. Early symptom onset is typically insidious, with gradual progression over weeks to months rather than acute presentation. Importantly, alarm features—including unintentional weight loss, progressive dysphagia, persistent vomiting, overt gastrointestinal bleeding, iron-deficiency anemia, or palpable abdominal mass—are absent in early FD and, if present, mandate urgent investigation to exclude organic pathology.

Typical symptoms constitute the core diagnostic criteria per Rome IV. These are grouped into two predominant, overlapping syndromes: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). PDS is defined by bothersome postprandial fullness occurring at least several times per week and/or early satiation that interferes with normal food intake, both present for at least three months with symptom onset at least six months prior to diagnosis. EPS is characterized by episodic, centrally located, non-colicky epigastric pain or burning occurring at least once weekly, lasting minutes to hours, and not relieved solely by defecation or antacids. Pain is typically unrelated to bowel habits and does not meet criteria for biliary colic or cardiac origin. Notably, many patients exhibit mixed features of both PDS and EPS, reflecting underlying pathophysiological overlap involving visceral hypersensitivity, impaired gastric accommodation, delayed gastric emptying (in ~30–40%), and altered duodenal mucosal barrier function with low-grade immune activation.

Accompanying symptoms are common but not required for diagnosis. These include belching (often air-swallowing related), epigastric or retrosternal burning without typical gastroesophageal reflux disease (GERD) patterns (i.e., not predominantly supine or nocturnal), mild nausea without vomiting, and subjective bloating—distinct from objective abdominal distension seen in irritable bowel syndrome (IBS). Some patients report heightened anxiety or somatic awareness related to meal anticipation, termed 'meal-related hypervigilance,' which may amplify symptom perception. Sleep disturbance and fatigue are frequently reported, likely secondary to chronic discomfort and associated psychological comorbidity rather than direct pathophysiology. Importantly, gastrointestinal symptoms do not correlate reliably with objective motility or acid measurements, underscoring the biopsychosocial nature of FD.

Complications of functional dyspepsia are primarily functional and psychosocial rather than structural or life-threatening. Chronic symptoms lead to significant impairment in health-related quality of life, reduced work productivity, and increased healthcare utilization. Patients are at elevated risk for developing comorbid functional disorders, particularly IBS (with up to 50% comorbidity), functional chest pain, and functional constipation. Psychological sequelae—including generalized anxiety disorder, depression, and illness-related catastrophizing—are prevalent and bidirectionally reinforce symptom severity and persistence. While FD itself does not predispose to malignancy or structural complications, prolonged symptom burden may result in iatrogenic harm, such as unnecessary endoscopies, prolonged proton pump inhibitor (PPI) use leading to rebound acid hypersecretion or micronutrient deficiencies (e.g., magnesium, vitamin B12), or inappropriate surgical referrals.

Diagnosis relies on a positive, symptom-based approach supplemented by judicious exclusionary testing. Rome IV criteria require symptom onset at least six months prior to diagnosis and fulfillment of criteria for at least three months. Initial evaluation includes comprehensive history (focusing on symptom pattern, temporal relationship to meals, presence/absence of alarm features, medication use, psychosocial stressors) and physical examination (typically unremarkable except for possible mild epigastric tenderness). First-line investigations include age- and risk-stratified upper endoscopy to rule out peptic ulcer disease, gastric cancer, eosinophilic gastritis, or celiac disease—particularly in patients ≥60 years, those with alarm features, or those from high gastric cancer prevalence regions. Serologic testing for Helicobacter pylori is recommended; if positive, eradication therapy is initiated, followed by symptom reassessment. Routine gastric emptying scintigraphy or electrogastrography is not indicated unless there is strong clinical suspicion of gastroparesis (e.g., severe early satiety with documented delayed emptying and no diabetes or neuropathy). Breath testing for small intestinal bacterial overgrowth (SIBO) or lactose intolerance lacks evidence for routine use in FD.

Differential diagnosis is critical to avoid misclassification. Organic causes must be rigorously excluded: peptic ulcer disease (often with nocturnal pain relieved by food/antacids), erosive GERD (predominantly supine/nighttime heartburn, response to PPIs), gastric or esophageal malignancy (alarm features), chronic pancreatitis (steatorrhea, weight loss, imaging abnormalities), gallstone disease (right upper quadrant pain radiating to back/shoulder, ultrasonographic evidence), and celiac disease (diarrhea, anemia, positive serology). Functional mimics include IBS (abdominal pain associated with altered bowel habits, predominantly lower abdominal), functional chest pain (non-cardiac, non-esophageal), and globus pharyngeus (sensation of lump in throat without dysphagia). Systemic conditions such as hyperparathyroidism (hypercalcemia-induced nausea), thyroid dysfunction (especially hypothyroidism causing delayed motility), and connective tissue disorders (e.g., scleroderma with gastroparesis) warrant consideration in atypical presentations. Psychiatric disorders—including somatic symptom disorder and illness anxiety disorder—may present with prominent GI complaints but require careful assessment of cognitive and behavioral features beyond symptom reporting. Ultimately, FD remains a diagnosis of exclusion grounded in phenomenology, pathophysiology-informed clinical reasoning, and shared decision-making.

Functional dyspepsia (FD) is a chronic, heterogeneous disorder characterized by persistent or recurrent epigastric discomfort—including postprandial fullness, early satiation, epigastric pain, or burning—in the absence of structural, metabolic, or systemic disease that explains the symptoms. Diagnosed using Rome IV criteria after excluding organic pathology (e.g., peptic ulcer disease, gastric malignancy, celiac disease, or biliary tract disorders) via upper endoscopy, abdominal ultrasound, and appropriate laboratory testing, FD affects approximately 15–20% of the global population and imposes substantial socioeconomic burden. Management is individualized, symptom-driven, and grounded in a biopsychosocial model—emphasizing patient education, lifestyle modification, pharmacotherapy, and psychosocial support. Surgical intervention has no role in FD, as it is not an anatomical or obstructive disorder.

Conservative treatment forms the cornerstone of FD management. First-line strategies include dietary counseling: patients are advised to eat smaller, more frequent meals; avoid known triggers such as fatty foods, caffeine, carbonated beverages, spicy foods, and alcohol; and maintain regular meal timing to stabilize gastric motility and reduce visceral hypersensitivity. Weight optimization is recommended for overweight or obese individuals, as adiposity correlates with low-grade gastric inflammation and delayed gastric emptying. Smoking cessation is strongly encouraged due to nicotine’s inhibitory effect on lower esophageal sphincter pressure and gastric accommodation. Stress reduction techniques—including cognitive behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), and gut-directed hypnotherapy—are evidence-based adjuncts shown to improve symptom severity and quality of life in randomized controlled trials. Patient education is critical: clinicians should explain the benign nature of FD, clarify the absence of cancer risk, and normalize symptom fluctuations to mitigate health anxiety and reduce unnecessary diagnostic repetition.

Pharmacologic therapy is initiated when conservative measures fail or symptoms significantly impair daily functioning. Prokinetic agents remain first-line for predominant motility-related symptoms (e.g., postprandial fullness, early satiation). Acotiamide—a reversible acetylcholinesterase inhibitor approved in Japan and increasingly used off-label in China and Europe—enhances gastric accommodation and accelerates gastric emptying with favorable tolerability. Domperidone (where available and appropriately monitored for cardiac safety) and low-dose erythromycin (a motilin receptor agonist) are alternatives, though erythromycin use is limited by tachyphylaxis. For epigastric pain or burning, acid-suppressive therapy is empirically trialed despite normal endoscopic findings: proton pump inhibitors (PPIs) at standard doses (e.g., omeprazole 20 mg once daily) for 4–8 weeks demonstrate modest but statistically significant benefit over placebo in meta-analyses, particularly in patients with overlapping gastroesophageal reflux symptoms or histologic evidence of low-grade gastric inflammation. H2-receptor antagonists may be considered for milder cases or PPI intolerance. Antidepressants—specifically low-dose tricyclic antidepressants (TCAs) like amitriptyline (10–25 mg at bedtime) or selective serotonin reuptake inhibitors (SSRIs)—are indicated for refractory FD with comorbid anxiety, depression, or central sensitization. These agents modulate descending pain inhibition pathways and improve visceral perception independent of mood effects. Emerging therapies under investigation include potassium-competitive acid blockers (P-CABs) and novel 5-HT4 receptor agonists, though none are yet FDA- or NMPA-approved specifically for FD.

Surgical treatment has no established indication in functional dyspepsia. Unlike mechanical obstruction or neoplastic disease, FD lacks surgically correctable pathology. Procedures such as fundoplication, pyloroplasty, or gastric resection are contraindicated and carry unacceptable risks—including dumping syndrome, bile reflux, nutritional deficits, and persistent symptoms—without evidence of efficacy. Misdiagnosis leading to unnecessary surgery remains a serious iatrogenic concern; thus, rigorous exclusion of organic disease and multidisciplinary reassessment are mandatory before considering any invasive intervention.

China offers distinct advantages in FD management, rooted in integrated clinical infrastructure and evolving evidence-based practice. Major tertiary hospitals—such as Peking Union Medical College Hospital, Zhongshan Hospital (Fudan University), and West China Hospital—employ standardized Rome IV–based diagnostic protocols, high-resolution manometry, and gastric emptying scintigraphy for phenotyping (e.g., postprandial distress syndrome vs. epigastric pain syndrome). Acotiamide is widely accessible and reimbursed under China’s National Reimbursement Drug List, facilitating early prokinetic use. Traditional Chinese Medicine (TCM) integration is uniquely robust: evidence-informed TCM patterns (e.g., liver-stomach disharmony, spleen-stomach deficiency) guide personalized herbal formulas (e.g., Xiangsha Liujunzi Tang or Banxia Xiexin Tang), acupuncture at ST36 (Zusanli), PC6 (Neiguan), and auricular therapy—all supported by RCTs demonstrating synergistic symptom reduction when combined with conventional care. Furthermore, China’s national FD registry and multicenter studies (e.g., the CHINA-FD cohort) accelerate real-world data generation, informing local guidelines updated annually by the Chinese Society of Gastroenterology.

Recovery advice emphasizes long-term self-management and realistic expectations. Patients should understand FD is often chronic but controllable—not curable—and symptom remission may fluctuate. A symptom diary tracking food intake, stressors, sleep, and symptom intensity helps identify personal triggers and assess treatment response. Regular physical activity (≥150 min/week moderate-intensity exercise) improves autonomic balance and gastric motility. Sleep hygiene—consistent bedtime, avoidance of late-night meals, and elevation of head-of-bed—is essential, given the bidirectional relationship between sleep disruption and visceral hypersensitivity. Follow-up intervals should be tailored: stable patients every 3–6 months; those initiating new medications or psychological interventions every 4–8 weeks. Referral to dietitians, clinical psychologists, or TCM practitioners is encouraged for multimodal support. Finally, patients must be counseled to avoid self-medication with NSAIDs or unregulated supplements, which may exacerbate mucosal irritation or drug interactions. With comprehensive, patient-centered care, >70% of individuals achieve meaningful symptom improvement and restored functional capacity within 6–12 months.